Integrated Biopharma Inc Revenue Growth Rates (INBP), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Integrated Biopharma Inc  (INBP)
 

INBP's Revenue Growth by Quarter and Year

Integrated Biopharma Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

INBP Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter June 9.80
3rd Quarter March 9.72
2nd Quarter December 11.03
1st Quarter September 12.02
FY 42.57

INBPs Annual Revenue
Integrated Biopharma Inc's Revenue in the fiscal year 2026 $ 43.87 millions
Integrated Biopharma Inc's Revenue in the fiscal year 2025 $ 53.56 millions
Integrated Biopharma Inc's Revenue in the fiscal year 2024 $ 49.88 millions
Integrated Biopharma Inc's Revenue in the fiscal year 2023 $ 50.06 millions
Integrated Biopharma Inc's Revenue in the fiscal year 2022 $ 56.25 millions




INBP Revenue fourth quarter 2025 Y/Y Growth Comment
Integrated Biopharma Inc reported fall in Revenue in the fourth quarter 2025 by -32.3% to $ 9.80 millions, from the same quarter in 2024.
The drop in the fourth quarter 2025 Integrated Biopharma Inc's Revenue compares unfavorably to the Company's average Revenue increase of 18.21%.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 86 other companies have achieved higher Revenue growth. While Integrated Biopharma Inc' s Revenue drop of -32.3% ranks overall at the positon no. 1697 in the fourth quarter 2025.


INBP Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter June -32.3 % 1.33 % 15.35 % -6.71 %
3rd Quarter March -28.27 % 10.61 % -6.49 % -16.19 %
2nd Quarter December -9.37 % 15.68 % -14.12 % -16.04 %
1st Quarter September -10.1 % 4.21 % 4.06 % -3.29 %
FY   -20.53 % 7.38 % -0.36 % -

Financial Statements
Integrated Biopharma Inc's fourth quarter 2025 Revenue $ 9.80 millions INBP's Income Statement
Integrated Biopharma Inc's fourth quarter 2024 Revenue $ 14.47 millions Quarterly INBP's Income Statement


INBP Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter June 0.78 % 6.79 % 16.57 % -5.5 %
3rd Quarter March -11.88 % 11.34 % 16.44 % 6.94 %
2nd Quarter December -8.24 % -8.98 % -18 % -0.65 %
1st Quarter September -16.93 % -6.37 % 3.63 % -7.08 %
FY (Year on Year)   -20.53 % 7.38 % -0.36 % -


Back to INBP Growth rate Comparisons >> Back to INBP Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #87
Healthcare Sector #245
Overall #1697

Revenue Y/Y Growth Statistics
High Average Low
346.88 % 18.21 % -15.14 %
(Sep. 30, 2015)   (Mar 31 2023)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #87
Healthcare Sector #245
Overall #1697
Revenue Y/Y Growth Statistics
High Average Low
346.88 % 18.21 % -15.14 %
(Sep. 30, 2015)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Integrated Biopharma Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
24.47 % 0.7 % -25.25 %
(Dec 31 2019)  


INBP's IV. Quarter Q/Q Revenue Comment
Integrated Biopharma Inc achieved in the IV. Quarter 2025 above company average sequential Revenue growth of 0.78%, to $ 9.80 millions, from $9.72 millions in the third quarter.

Within Major Pharmaceutical Preparations industry 89 other companies have achieved higher Revenue quarter on quarter growth. While Integrated Biopharma Inc's Revenue growth quarter on quarter, overall rank is 2175.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #90
Healthcare Sector #262
Overall #2175
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #90
Healthcare Sector #262
Overall #2175
Revenue Q/Q Growth Statistics
High Average Low
24.47 % 0.7 % -25.25 %
(Dec 31 2019)  


INBP's IV. Quarter Q/Q Revenue Comment
Integrated Biopharma Inc achieved in the IV. Quarter 2025 above company average sequential Revenue growth of 0.78%, to $ 9.80 millions, from $9.72 millions in the third quarter.

Within Major Pharmaceutical Preparations industry 89 other companies have achieved higher Revenue quarter on quarter growth. While Integrated Biopharma Inc's Revenue growth quarter on quarter, overall rank is 2175.


Integrated Biopharma Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 47.24 $ 51.07 $ 52.21 $ 53.56 $ 53.38
Y / Y Revenue Growth (TTM) -11.5 % -1.93 % 3.54 % 7.37 % 11.24 %
Year on Year Revenue Growth Overall Ranking # 922 # 353 # 1716 # 2117 # 2107
Seqeuential Revenue Change (TTM) -7.49 % -2.19 % -2.52 % 0.35 % 2.5 %
Seq. Revenue Growth (TTM) Overall Ranking # 1697 # 454 # 1609 # 1665 # 1868


Cumulative Revenue growth Comment
Integrated Biopharma Inc's cumulative 12 months Revenue continue to fall, but on the faster rate at -11.5% year on year, at Mar 31 2026 compare to the -1.93% decrease at Dec 31 2025. If the Integrated Biopharma Inc's fiscal year would end at Mar 31 2026, annual Revenue would be $47 millions.

In the Healthcare sector 163 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 353 to 922.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 87
Healthcare Sector # 164
Overall # 922

Revenue TTM Y/Y Growth Statistics
High Average Low
346.88 %
 18.21 %
-15.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 87
Sector # 245
S&P 500 # 1697
Cumulative Revenue growth Comment
Integrated Biopharma Inc's cumulative 12 months Revenue continue to fall, but on the faster rate at -11.5% year on year, at Mar 31 2026 compare to the -1.93% decrease at Dec 31 2025. If the Integrated Biopharma Inc's fiscal year would end at Mar 31 2026, annual Revenue would be $47 millions.

In the Healthcare sector 163 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 353 to 922.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 87
Healthcare Sector # 164
Overall # 922

Revenue TTM Y/Y Growth Statistics
High Average Low
346.88 %
18.21 %
-15.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 87
Sector # 245
S&P 500 # 1697




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
INBP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Integrated Biopharma Inc Revenue Growth Rates (INBP), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Integrated Biopharma Inc (CIK 1016504).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-26-031241
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Integrated Biopharma Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.